On April 14, Tianyu shares (300702) issued an announcement that the company's wholly-owned subsidiary Nord Pharmaceuticals recently received the "Drug Registration Certificate" for pravastatin sodium tablets approved and issued by the State Drug Administration. The drug dosage form is tablets with a specification of 40mg. It belongs to Class 4 chemical drugs. The drug approval number is National Medicine Standard H20253858, and the approval period is until April 7, 2030. It is suitable for hyperlipidemia and familial hypercholesterolemia.

According to market data, the sales of pravastatin sodium tablets in domestic sample hospitals and urban physical pharmacies in 2023 are about 1.024 billion yuan. As of March 31, 2025, the company and its subsidiaries have invested approximately 9.26 million yuan in research and development on this drug.

The announcement pointed out that the acquisition of the drug registration certificate will further enrich the company's preparation varieties and specifications, and is expected to increase the company's preparation business revenue, help improve market competitiveness, and have a positive impact on operating performance.

https://finance.eastmoney.com/a/202504143376312839.html